Research programme: photodynamic therapeutics - Genisphere/University of Pennsylvania

Drug Profile

Research programme: photodynamic therapeutics - Genisphere/University of Pennsylvania

Alternative Names: Photodynamic 3DNA® therapeutics

Latest Information Update: 12 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genisphere; University of Pennsylvania
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 22 Mar 2016 Genisphere's 3DNA® is available for licensing as of 22 Mar 2016.
  • 22 Mar 2016 Preclinical development in Breast cancer in USA (unspecified route)
  • 22 Mar 2016 Genisphere and University of Pennsylvania agree to co-develop photodynamic therapeutics for Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top